Home
About
Company Profile
Culture
Qualification
Facility
Products
Neuro Intervention
Peripheral Intervention
Cardiovascular Intervention
Customization
Blog
Company News
Industry News
Contact Us
中文版
Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel a Structured Market Rally; AI in Healthcare Opens Up New Growth Opportunities
During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance.
01
2025
/
03
Pharmaceutical and Biotechnology Industry Watch: AI-Driven Healthcare Applications Accelerate Deployment; Breakthroughs in Payment-Policy for Innovative Drugs
Recently, the pharmaceutical and biotechnology sector has exhibited a pronounced structural market trend, driven by the deep integration of AI technologies with healthcare applications, which is spurring industry-wide upgrades. At the same time, policy support for innovative drugs continues to strengthen, creating multiple favorable factors for the sector.
With the concerted support of 17 government departments, the latest policies for the biopharmaceutical industry in the Jiangsu Pilot Free Trade Zone have been unveiled!
Recently, the “Policy Measures for Coordinated Support from Relevant Provincial Departments for the Open and Innovative Development of the Biopharmaceutical Industry in the China (Jiangsu) Pilot Free Trade Zone” (hereinafter referred to as the “Policy Measures”) were officially released!
Medical Device Industry Development Report: Significant Market Potential in Countries Along the Belt and Road
Recently, the “Blue Book on Medical Devices: Report on the Development of China’s Medical Device Industry (2018),” jointly released in Beijing by the China Association for Pharmaceutical Regulatory Research and the Social Sciences Academic Press, stated that since the Belt and Road Initiative was proposed in 2013, demand for Chinese medical device products has increased among countries along the Belt and Road.
Interpretation of the Special Review Procedure for Innovative Medical Devices
One of the review criteria for innovative medical devices is that the applicant must legally hold an invention patent in China for the product’s core technology. Given that there are instances where applications for core-technology invention patents have been published by the patent administrative department under the State Council but ultimately not granted, a preliminary evaluation of the product’s core technical solution has been added.